anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A cosmetic composition containing a liposome having medicinal herb extracts is provided to maximize penetration effect to skin and hair and promoter hair growth. CONSTITUTION: A cosmetic composition for hair care contains: 0.01-50 weight% of scalp targeted liposome having Phellinus linteus, Thuja orientalis L. Portulaca oleracea L., Rumex crispus L., Zingiber officinale, Asian Celandine, and Artermisia argyi Lev. Et Vant. extract mixture; and 0.01-50 weight% of hair targeted liposome having henna, Houttuynia cordata Thunberg, Multiflorus, Acorus calamus var. angustatus, Saururus chinensis, and black soybean extract. The diameter of the average particle of the scalp targeted liposome is 100-200 nm. The diameter of the averge particle of the hair targeted liposome is 50-150 nm.
PURPOSE:To obtain a coronary vasodilator applicable without causing the increase of pulse rate and blood pressure by using leaf of nicotineless tobacco and/or a water-soluble component of the combustion smoke tar of the leaf as active components. CONSTITUTION:The objective agent contains leaf of nicotineless tobacco having a nicotine-content of <0.30wt.% and/or a water-soluble component of the combustion smoke tar of the leaf (hereinafter called simply as component A) as active components. The component may be used as a peroral drug by conventional process of as a parenteral injection using distilled water, physiological saline water, aqueous solution of glucose, etc. It is administered at a dose of 0.1-5mg of the component A per 1kg of body weight. The component A may be added to a combustible material to form a cigarette or to a food to be used as a chewing gum. It is useful for the remedy and prevention of heart stroke by increasing the coronary blood flow without accompanying side actions undesirable to coronary function, e.g. increase of blood pressure and pulse rate and the contraction of peripheral vessel.
This is a randomized, double-blind, placebo-controlled, multiple-ascending dose study of orally administered AVE8112 in patients with Parkinson's Disease (PD). Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Dosing for subsequent cohorts will only proceed, and the dose level selected, after the safety and tolerability of the previous cohort has been reviewed. Doses are planned to be 1.0, 2.0, 3.0, and 4.0 mg once a day for 14 days. These are planned treatments, but doses may be modified based on safety review of previous cohort(s). In addition, cohorts may be added to reconfirm a previously administered dose, and/or a titration strategy may be employed to reach a desired dose.

Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo. Subsequent dosing will occur on an outpatient basis. Patients will receive telephone calls on Days 3 and 10 to monitor for adverse events (AEs) and concomitant medications, and will also be assessed in the clinic on Study Days 7 (outpatient), 14 (outpatient), and 28 (± 3 days) (Follow-up visit). Safety assessments will include physical examinations, vital signs, ECGs, clinical laboratory evaluations, Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), and Columbia Suicide Severity Rating Scale (C-SSRS). Pharmacodynamic assessment will include the Parkinson's Disease Cognitive Rating Scale (PD-CRS).
In Taiwan, aging is happening at a fast pace. The Taiwan Ministry of Interior officially announced that Taiwan will become an aged society in April 2018 and is expected to transition into a hyper-aged society within eight years. Critically, scholars recognize that optimizing cognitive activity and wellbeing influences quality of life in a late life which in turn is a key factor for successful aging. To alleviate the social and economic impact of aging, as well as impact on families, there is a need for studying anti-aging approaches. The World Health Organization suggests that the general public should have a healthy lifestyle which includes participating in activities for physical health, as well as cognitive and mental health involving maintaining social interactions. This present research is part of a broader integrated program in which the purpose is to promote and study the efficacy of forest therapy on physical health, and cognitive and mental health in older adults. The study site is located at the National Taiwan Science Education Center (NTSEC) which includes wetlands, waterfronts, green-spaces and urban parks. The investigators will evaluate two types of interventions for participants, "forest therapy program" and "fitness program" for older adults. The study approach applies a between-subjects and pretest-posttest design. The investigators will collect participants' physical data, psychological responses, and cognitive performance in the course of both programs. By comparing these data before and after the intervention programs, the investigators seek to understand the both programs' effects on physical health, and cognitive and mental health. In addition, the investigators will elucidate the efficacy of the forest therapy program through measurement of the changes in physical, cognitive, and mental health performance and status indicators. The forest therapy and fitness programs at National Taiwan Science Education Center (NTSEC), along with a robot programming training and tinkering activities that are part of the broader project, acts as a public education and service window towards addressing cognitive aging issues in Taiwan. It should be further noted that this will be a critical platform for obtaining ecological research data on a novel class of cognitive interventions for cognitive aging using psychological and brain imaging techniques to bridge critical neural mechanistic knowledge gaps.
Topotecan 0.4 mg/m\^2/day administered via continuous infusion for 9 days beginning on Day 1, every 21 days cycle; erlotinib 150 mg daily for 9 days every 21 days cycle. Both drugs will be given for a minimum of 2 cycles.
The present invention provides a novel albumin-free preparation of factor VIII has a high amount of salt and a low concentration of sugar and of glycine. The high salt provides stability and an elegant cake structure as the major crystalline component. The low amounts of sugar and glycine provide a complex amorphous matrix together with some amorphous non-crystallized salt for stabilization of factor VIII. This formulation is particularly suitable for B-domain deleted factor VIII that requires a high ionic strength environment for stability. The addition of low amount of glycine to the sucrose prevents the crystallization of salt. This results in an amorphous matrix comprising of glycine, sucrose, and salt. This amorphous matrix provides a stabilizing environment where factor VIII is protected by three stabilizers; amino acid (glycine), sugar (sucrose or trehalose), and salt (NaCl). Such an amorphous matrix that can stabilize the factor VIII across lyophilization and during storage as a lyophile.
Recent studies focused on exploring phosphodiesterase type 5 inhibitors (PDE5Is)-related hearing impairment. This study aimed to comprehensively explore real-world hearing impairment associated with PDE5Is based on the US Food and Drug Administration Adverse Event Reporting System (FAERS). The characteristics and correlation of PDE5Is-related hearing impairment reported in the FAERS database from the fourth quarter of 2003 to the second quarter of 2023 were analyzed using disproportionality analysis. The Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs) were used to analyze the adverse events (AEs) of hearing impairment. A total of 1,438 reported cases of hearing impairment were associated with four PDE5Is, revealing statistically significant reporting odds ratio (ROR), proportional reporting ratio (PRR), and information component (IC) with the SMQ. The average age of all patients was more than 55 years, over 70% of AEs were reported in men. Most of the reported cases were from the United States. Reports for all the drugs indicated an increase since 2008, except for avanafil. This study showed that the disability rates of PDE5Is were 8.14-40%, the rates of initial or prolonged hospitalization were 6.21-10.24%, and the rates of required intervention were 3.31-9.45%. The pharmacovigilance study identified a potential risk of hearing impairment associated with PDE5Is, indicating the need for continuous monitoring and appropriate management.
The invention provides a bispecific antibody and application of the bispecific antibody and T cells thereof in preparation of tumor treatment medicines, wherein the bispecific antibody comprises a first functional region targeting CD3 and a second functional region targeting PD-L1, and the first functional region is of an scFv structure and comprises a heavy chain variable region with an amino acid sequence shown as SEQ ID NO. 1 and a light chain variable region with an amino acid sequence shown as SEQ ID NO. 2; the second functional region is in a Fab structure and comprises a heavy chain variable region with an amino acid sequence shown as SEQ ID NO. 3 and a light chain variable region with an amino acid sequence shown as SEQ ID NO. 4. The bispecific antibody adopts an IgG type structure, so that the half life in vivo can be prolonged, and the rejection reaction can be reduced. T activation patterns are optimized, and the activation state of T cells in vivo can be maintained by using a combined stimulation strategy of TGF-beta, IL-25 and IL-33. The bispecific antibody provided by the invention can inhibit the growth of tumor cells, regulate the expression level of immune factors and prolong the production period of animals by being combined with activated T cells.
A cleansing composition for removing the make-up, which contains a mixture of cellulose microbead and anionic surfactant is provided to clean a face with excellent cleansing effect without skin irritation. A cleansing composition for removing the make-up comprises 5-25% by weight of mixture of cellulose microbead and anionic surfactant in a weight ratio of 1:1-1:1.5, 10-35% by weight of soap component, and 0-40% by weight of water. The cellulose microbead is 100um of particle which under 10um of cellulose bead is aggregated and removes the make-up in a minute particle without the irritation. The anionic surfactant is alkyl phosphate or alkylester phosphate. With the composition, the make-up can be removed and washed. The high fatty acid is Lauryl acid, myristate, palmitic acid or stearyl acid.
BACKGROUND: Mesenchymal stem cells (MSCs) are attracting attention as a promising cell-based therapy for the treatment of liver fibrosis or cirrhosis. However, the strategies and potential mechanisms of MSCs therapy need further investigation. The CXCL12/CXCR4/CXCR7 chemokine axis is well known to regulate cell migration and is involved in the regulation of liver fibrosis. This study aims to treat MSCs with a CXCR7-specific agonist to evaluate its therapeutic effects on hepatic fibrosis and potential mechanisms.
METHODS: TC14012, a potent agonist of CXCR7, has been used to pretreat human umbilical cord-derived MSCs (UC-MSCs) and assess its effect on proliferation, apoptosis, migration, immunoregulation, and gene regulatory network. Then, CCl4-induced liver fibrosis mice models were used to evaluate the therapeutic effect and mechanism of TC14012-treated UC-MSCs for treating hepatic fibrosis.
RESULTS: TC14012 increased CXCR7 expression in UC-MSCs. Notably, co-culture of liver sinusoidal endothelial cells (LSEC) with TC14012-pretreated UC-MSCs increased CXCR7 expression in LSEC. Additionally, TC14012 promoted cell migration and mediated the immunoregulation of UC-MSCs. Compared to UC-MSCs without TC14012 pretreatment, UC-MSCs treated with TC14012 ameliorated live fibrosis by restoring CXCR7 expression, reducing collagen fibril accumulation, inhibiting hepatic stellate cells activation, and attenuating the inflammatory response.
CONCLUSION: This study suggests that TC14012 pretreatment can enhance the therapeutic effects of UC-MSCs on liver fibrosis, mainly by promoting the migration and immunoregulation of MSCs.
The human colonic commensal enterotoxigenic Bacteroides fragilis (ETBF) is associated with chronic colitis and colon cancer. ETBF colonization induces colitis via the Bacteroides fragilis toxin (BFT). BFT secreted by ETBF cause colon inflammation via E-cadherin cleavage/NF-κB signaling. ETBF promotes colon tumorigenesis via interleukin 17A (IL-17A)/CXCL-dependent inflammation, but its bioactive therapeutics in ETBF-promoted tumorigenesis remain unexplored. In the current study, we investigated the caffeic acid phenethyl ester (CAPE) in the murine model of ETBF colitis and tumorigenesis. In this study, we observed that CAPE treatment mitigated inflammation induced by ETBF in mice. Additionally, our findings indicate that CAPE treatment offers protective effects against ETBF-enhanced colon tumorigenesis in a mouse model of colitis-associated colon cancer induced by azoxymethane (AOM) and dextran sulfate sodium. Notably, the decrease in colon tumorigenesis following CAPE administration correlates with a reduction in the expression of IL-17A and CXCL1 in the gastrointestinal tract. The molecular mechanism for CAPE-induced protection against ETBF-mediated tumorigenesis is mediated by IL-17A/CXCL1, and by NF-κB activity in intestinal epithelial cells. Our findings indicate that CAPE may serve as a preventive agent against the development of ETBF-induced colitis and colorectal cancer (CRC).
A method for treatment of a disorder in an organism characterized by abnormal cellular signal transduction is described. The disorder may be characterized by an abnormal level of interaction between a signalling component such as SHC and an RTK of the Trk family, or the interaction between particular SH3 and MP domains (such as an interaction between an SH3 domain and a DYN domain). The method includes disrupting or promoting that interaction (or signal) in vivo. The method also involves inhibiting the activity of the complex formed between the individual molecules. A method for diagnosis of such a disease or condition by detecting the level of such interaction as an indication of that disease or condition is also described. Also, a method for screening for an agent useful for treatment of such a disease or condition by assaying potential agents for the ability to disrupt or promote that interaction is described. The invention also features peptides consisting essentially of particular MP, DYN and SH3 domains.
The invention relates to a method for producing a dental brace comprising soft and hard brace zones. The materials of the two brace zones have the same plastic base. The soft brace zone (17) of the dental brace (01, 13, 14) is made from a soft, elastic formulation containing at least one monomer or oligomer. Said brace zone is joined to a dimensionally stable, hard brace zone (18) by means of a polymerization process, without using an additional adhesive. The monomer or oligomer is characterized in that the same dissolves in at least one polymer of the hard brace zone, particularly in its own polymer. The inventive dental brace fits perfectly and is very comfortable as a result of the soft brace zone thereof while having a long service life due to the monolithic embodiment thereof. Furthermore, the dental brace can be repaired and can be colored in any color as the same is made from material having the same plastic base.
Shilianhua (SLH) extract has been discovered to display bioactivity in the regulation of fatty acid and glucose metabolism, and in inhibition of an inflammatory response. In addition, an active fraction of SLH extract has been characterized. An active SLH extract protected against insulin resistance through multiple mechanisms, including inhibition of IKK/NF-κB, stimulation of adiponectin secretion, promotion of fatty acid oxidation, and activation of p38. SLH can be used in the prevention and treatment of diseases in which insulin resistance plays a major role, which includes hyperglycemia, cardiovascular diseases (such as hypertension, heart disease), stroke, renal failure, blindness, and non-traumatic limb amputation. SLH can be used to treat obesity and hyperlipidemia-related diseases by promotion of fatty acid oxidation and energy expenditure. SLH extracts may be used for prevention and treatment of inflammation and oxdative stress, and other diseases in which NF-κB plays a major role, such as arthritis, aging and cancer.
Disclosed is a method of obtaining selectable transgenic stem cells of a vertebrate by transfecting a male germ cell with a transfection mixture comprising a nucleic acid construct containing a transcriptional unit of a stem cell-specific promoter, for example, a cyclin A1 promotor, operatively linked to a gene encoding a fluorescent or light-emitting reporter protein. The transfection mixture is a composition for transfection, in vivo or ex vivo, of a vertebrate's male germ cells, which comprises a nucleic acid or transgene, and a gene delivery system, and optionally a protective internalizing agent, such as an endosomal lytic agent, a virus or a viral component, which is internalized by cells along with the transgene and which enhances gene transfer through the cytoplasm to the nucleus of the male germ cell. In stem cells, other than germ cells, grown in vivo, expression of the reporter gene from a cyclin A1 promoter is facilitated by preventing methylation of promoter DNA by the use of flanking insulator elements in the nucleic acid construct. Alternatively, inhibitors of DNA methylation can be used in an in vitro growth medium. A kit contains components of the transfection mixture. Selectable transgenic stem cells have stably integrated the DNA, and non-human transgenic vertebrates comprise these selectable transgenic stem cells.
For infants randomized to the human milk cream group, the human milk (either mother's own or donor) being provided to the infant will be tested each time a new container is used to prepare feedings. The test will be for the caloric content of the milk using a commercially available device provided for this purpose. If the caloric level falls below 20 kcal/oz for any test, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. The amount added will be calculated to the nearest mL rounding down for 0.1-0.4mL and up for 0.5-0.9 mL to avoid imprecision due to the measuring device used in the nutrition preparation area.
Although liver transplantation (LT) is an effective strategy for end-stage liver diseases, the shortage of donor organs and the immune rejection hinder its widespread implementation in clinical practice. Mesenchymal stem cells (MSCs) transplantation offers a promising approach for patients undergoing liver transplantation due to their immune regulatory capabilities, hepatic protection properties, and multidirectional differentiation potential. In this review, we summarize the potential applications of MSCs transplantation in various LT scenarios. MSCs transplantation has demonstrated effectiveness in alleviating hepatic ischemia-reperfusion injury, enhancing the viability of liver grafts, preventing acute graft-versus-host disease, and promoting liver regeneration in split LT therapy. We also discuss the clinical progress, and explore the immunomodulatory functions of MSCs in response to both adaptive and innate immune responses. Furthermore, we emphasize the interactions between MSCs and different immune cells, including T cells, B cells, plasma cells, natural killer cells, dendritic cells, Kupffer cells, and neutrophils, to provide new insights into the immunomodulatory properties of MSCs in adoptive cell therapy.
A node that is part of a network of nodes with access to a distributed ledger may receive a transaction request to perform one or more operations associated with the distributed ledger, wherein the one or more operations include causing a record of a transaction to be stored using the distributed ledger. The node may determine, based on credential information associated with the transaction request, whether to allow the one or more operations to be performed. The node may perform the one or more operations based on determining to allow the one or more operations to be performed. The one or more operations may include adding the record of the transaction to the distributed ledger. At least a subset of the content may be included in the record. The node may cause one or more other nodes, of the network of nodes, to have access to the distributed ledger.
Mangrove species are broadly classified as true mangroves and mangrove associates. The latter are amphibious plants that can survive in the intertidal zone and reproduce naturally in terrestrial environments. Their widespread distribution and extensive adaptability make them ideal research materials for exploring adaptive evolution. In this study, we de novo assembled two genomes of mangrove associates (the allotetraploid Barringtonia racemosa (2n = 4x = 52) and diploid Barringtonia asiatica (2n = 2x = 26)) to investigate the role of allopolyploidy in the evolutionary history of mangrove species. We developed a new allotetraploid-dividing tool Allo4D to distinguish between allotetraploid scaffold-scale subgenomes and verified its accuracy and reliability using real and simulated data. According to the two subgenomes of allotetraploid B. racemosa divided using Allo4D, the allopolyploidization event was estimated to have occurred approximately one million years ago (Mya). We found that B. racemosa, B. asiatica, and Diospyros lotus shared a whole genome duplication (WGD) event during the K-Pg (Cretaceous-Paleozoic) period. K-Pg WGD and recent allopolyploidization events contributed to the speciation of B. racemosa and its adaptation to coastal habitats. We found that genes in the glucosinolates (GSLs) pathway, an essential pathway in response to various biotic and abiotic stresses, expanded rapidly in B. racemosa during polyploidization. In summary, this study provides a typical example of the adaptation of allopolyploid plants to extreme environmental conditions. The newly developed tool, Allo4D, can effectively divide allotetraploid subgenomes and explore the evolutionary history of polyploid plants, especially for species whose ancestors are unknown or extinct.
A composition and method is disclosed for healing, preserving and penetration, and killing and preventing fungus growth on mammals with ungulates. In the preferred embodiment hoof lotion with a composition of linseed oil, lanolin, terpentine, pine tar, hydrogen peroxide, iodine and copper sulphate are blended and dissolved in a biocidal solution. It is sprayed on the affected area of the hoof, with a easy to use finger trigger spray nozzle that is fasten to a hand held bottle, to which the lotion in amounts sufficient to prevent fungi and the protection and maintenance of health on said mammals with ungulates adheres. Is evenly distributed in the composition such that the dispersal is uniformly. It is highly effective for killing and preventing fungal growths, and it heals cracks, brittle surfaces, dryness, and moisture problems in and around the coronet bands, sole, frog, walls, and heel. It is fast acting, quick drying and long lasting, and it is easy to apply, inexpensive to use and lacks the draw backs of prior methods, and composition.